AI across the RNA therapeutics lifecycle: discovery, development, and the road to personalized medicine
Nucleic Acid Insights · 12.11.2026 · 3 (9) · 637–643
DOI: 10.18609/nai.2026.084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Insights, online erschienen am 12.11.2026. Verfasst von Edward Miracco. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Jokūbas Leikauskas, Editor, Nucleic Acid Insights, speaks with Edward Miracco, Head of Enterprise AI Enablement, Moderna, about enterprise AI adoption, AI-driven lipid nanoparticle and neoantigen design, rare disease applications of mRNA, and the future of RNA therapeutics.
Zitieren
APA
Miracco, E. (2026). AI across the RNA therapeutics lifecycle: discovery, development, and the road to personalized medicine. Nucleic Acid Insights, 3(9), 637–643. https://doi.org/10.18609/nai.2026.084
Vancouver
Miracco E. AI across the RNA therapeutics lifecycle: discovery, development, and the road to personalized medicine. Nucleic Acid Insights. 2026;3(9):637–643. doi:10.18609/nai.2026.084
BibTeX
@article{Miracco2026,
author = {Miracco, Edward},
title = {AI across the RNA therapeutics lifecycle: discovery, development, and the road to personalized medicine},
journal = {Nucleic Acid Insights},
year = {2026},
volume = {3},
number = {9},
pages = {637–643},
doi = {10.18609/nai.2026.084}
}
EUVIMED